L1-CAM as a target for treatment of cancer with monoclonal antibodies

Anticancer Research

Volumn 29, Issue 12, 2009, Pages 4919-4931

  Weidle, Ulrich H ^a   Eggle, Daniela ^a   Klostermann, Stefan ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Isoforms; L1 CAM; Monoclonal antibodies; Review; Signaling; Tumorigenesis

Indexed keywords

ANTIBODY CONJUGATE; GENISTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CHCE7; MONOCLONAL ANTIBODY CHCE7 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LU 177; MONOCLONAL ANTIBODY CHCE7 CU 64; MONOCLONAL ANTIBODY CHCE7 CU 67; MONOCLONAL ANTIBODY CHCE7 I 131; MONOCLONAL ANTIBODY CHCE7 LU 177; MONOCLONAL ANTIBODY L1 11A CU 67; NERVE CELL ADHESION MOLECULE L1; NERVE CELL ADHESION MOLECULE L1 ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; APOPTOSIS; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL MIGRATION; CELL MOTILITY; COLORECTAL CANCER; DISEASE COURSE; DRUG POTENTIATION; DRUG TARGETING; HUMAN; KIDNEY CARCINOMA; KIDNEY TUBULE; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; NEUROENDOCRINE TUMOR; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN VARIANT; RADIOIMMUNOTHERAPY; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; NEOPLASMS; NEURAL CELL ADHESION MOLECULE L1;

EID: 75149178180     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Harris M: Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 5: 292-302, 2004.
2. Dalle S, Thieblemont C, Thomas L and Dumontet C: Monoclonal antibodies in clinical oncology. Anticancer Agents Med Chem 8: 523-532, 2008.
3. Adams GP and Weiner LM: Monoclonal antibody therapy of cancer: Antibody engineering and manufacture. Nature Biotechnol 23: 1147-1157, 2005.
4. Brümmendorf T and Rathjen FG: Structure/function relationships of axon-associated adhesion receptors of the immunoglobulin superfamily. Curr Opin Neurobiol 6: 584-593, 1996.
5. Grumet M: Cell adhesion molecules and their subgroups in the nervous system. Curr Opin Neurobiol 1: 370-376, 1991.
6. Hortsch M: Structural and functional evolution of the L1 family: are four adhesion molecules better than one? Mol Cell Neurosci 15: 1-10, 2000.
7. Coutellea O, Nyakatura G, Taudien S, Elgar G, Brenner S, Platzer M, Drescher B, Jouet M, Kenwrick S and Rosenthal A: The neural cell adhesion molecule L1: genomic organisation and differential splicing is conserved between man and the pufferfish Fugu. Gene 208: 7-15, 1998.
8. Hortsch M: The L1 family of neural cell adhesion molecules: old proteins performing new tricks. Neuron 17: 587-593, 1996.
9. Haspel J and Grumet M: The L1CAM extracellular region: a multi-domain protein with modular and cooperative binding modes. Front Biosci 8: s1210-1225, 2003.
10. Crossin KL and Krushel LA: Cellular signaling by neural cell adhesion molecules of the immunoglobulin superfamily. Dev Dyn 218: 260-279, 2000.
11. Bateman A, Jouet M, MacFarlane J, Du JS, Kenwrick S and Chothia C: Outline structure of the human L1 cell adhesion molecule and the sites where mutations cause neurological disorders. EMBO J 15: 6050-6059, 1996.
12. Yamasaki M, Thompson P and Lemmon V: CRASH Syndrome: Mutations in L1CAM correlate with severity of the disease. Neuropediatrics 28: 175-178, 1997.
13. Moya GE, Michaelis RC, Holloway LW, Sanchez JM: Prenatal diagnosis of L1 cell adhesion molecule mutations. Fetal Diagn Ther 17: 115-119, 2002.
14. Demyanenko GP, Tsai AY and Maness PF: Abnormalities in neuronal process extension, hippocampal development, and the ventricular system of L1 knockout mice. J Neurosci 19: 4907-4920, 1999.
15. Fransen E, D'Hooge R, Van Camp G, Verhoye M, Sijbers J, Feyniers E, Soriano P, Kamiguchi H, Willemsen R, Koekkoek SKE, De Zeeuw CI, De Deyn PP, Van der Linden A, Lemmom V, Kooy RF and Willems PJ: L1 knockout mice show dilated ventricles, vermis hypoplasia and impaired exploration patterns. Hum Mol Genet 7: 999-1009, 1998.
16. Gavert N, Sheffer M, Raveh S, Spaderna S, Shtutman M, Brabletz T, Barany F, Paty P, Notterman D, Domany E and Ben-Ze'ev A: Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis. Cancer Res 67: 7703-7712, 2007.
17. Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Gast D, Joumaa S, Zentgraf H, Fogel M and Altevogt DP: ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles. FASEB J 17: 292-294, 2003.
18. Kamiguchi H and Lemmon V: IgCAMs: bidirectional signals underlying neurite growth. Curr Opin Cell Biol 12: 598-605, 2000.
19. Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Smirnov A, Edler L, Ben-Arie A, Huszar M and Altevogt P: L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet 362: 869-875, 2003.
20. Fogel M, Huszar M, Altevogt P and Ben-Arie A: L1 (CD171) as a novel biomarker for ovarian and endometrial carcinomas. Expert Rev Mol Diagn 4: 455-462, 2004.
21. Daponte A, Kostopoulou E, Kollia P, Papamichali R, Vanakara P, Hadjichristodoulou C, Nakou M, Samara S, Koukoulis G and Messinis IE: L1 (CAM) (CD171) in ovarian serous neoplasms. Cancer Res 68: 1110-1118, 2008.
22. Zecchini S, Bianchi M, Colombo N, Fasani R, Goisis G, Casadio C, Viale G, Liu J, Herlyn M, Godwin AK, Nuciforo PG and Cavallaro U: The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Gynecol Oncol 104: 461-469, 2007.
23. Stoeck A, Gast D, Sanderson MP, Issa Y, Gutwein P and Altevogt P: L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. Clin Cancer Res 11: 7234-7242, 2005.
24. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, Atkins D and Wang Y: Novel genes associated with malignant melanoma but not benign melanocytic lesions. Int J Cancer 119: 549-555, 2006.
25. Meier F, Busch S, Gast D, Göppert A, Altevogt P, Maczey E, Riedle S, Garbe C and Schittek B: The adhesion molecule L1 (CD171) promotes melanoma progression. Ann Surg Oncol 14: 1703-1711, 2007.
26. Kim HS, Park, K Jun HJ, Yi SY, Han J, Ahn JS, Ahn, M-J, Kang, WK, Kim J and Hong H-J: Prognostic significance of L1 cell adhesion molecule (CAM) expression in pulmonary neuroendocrine tumors. J Thorac-Oncol 2, S 4, p S 440, 2007.
27. Boo YJ, Park JM, Kim J, Chae YS, Min BW, Um JW and Moon HY: L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer. Ann Surg Oncol 14: 1703-1711, 2007.
28. Kaifi JT, Reichelt U, Quaas A, Schurr PG, Wachowiak R, Yekebas EF, Strate T, Schneider C, Pantel K, Schachner M, Sauter G, Quaas A, and Izbicki JR: L1 is associated with micrometastatic spread and poor outcome in colorectal cancer. Mod Pathol 20: 1183-1190, 2007.
29. Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T and Ben-Ze'ev A: L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 168: 633-642, 2005.
30. Kaifi JT, Strelow A, Schurr PG, Reichelt U, Yekebas EF, Wachowiak R, Quaas A, Strate T, Schaefer H, Sauter G, Schachner M and Izbicki JR: L1 (CD171) is highly expressed in gastrointestinal stromal tumors. Mod Pathol 19: 399-406, 2006.
31. Kaifi JT, Zinnkann U, Yekebas EF, Schurr PG, Reichelt U, Wachowiak R, Fiegel HC, Petri S, Schachner M and Izbicki JR: L1 is a potential marker for poorly-differentiated pancreatic neuroendocrine carcinoma. World J Gastroenterol 12: 94-98, 2006.
32. Allory Y, Matsuoka Y, Bazille C, Christensen EI, Ronco P and Debiec H: The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas. Clin Cancer Res 11: 1190-1197, 2005.
33. Deichmann M, Kurzen H, Egner U, Altevogt P and Hartschuh W: Adhesion molecules CD171 (L1CAM) and CD24 are expressed by primary neuroendocrine carcinomas of the skin (Merkel cell carcinomas). J Cutan Pathol 30: 363-368, 2003.
34. Wachowiak R, Fiegel HC, Kaifi JT, Quaas A, Krickhahn A, Schurr PG, Entmann R, Schachner M, Kluth D, Sauter G and Izbicki JR: L1 is associated with favorable outcome in neuroblastomas in contrast to adult tumors. Ann Surg Oncol 14: 3575-3580, 2007.
35. Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P and Fogel M: Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol 37: 1000-1008, 2006.
36. Gavert N, Ben-Shmuel A, Raveh S and Ben-Ze'ev: L1-CAM in cancerous tissues. Expert Opin Biol Ther 8: 1750-1757, 2008.
37. Gast D, Riedle S, Issa Y, Pfeifer M, Beckhove P, Sanderson MP, Arlt M, Moldenhauer G, Fogel M, Krüger A and Altevogt P: The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies. Oncogene 27: 1281-1289, 2008.
38. Silletti S, Yebra M, Perez B, Cirulli V, McMahon M and Montgomery AM: Extracellular signal-regulated kinase (ERK)-dependent gene expression contributes to L1 cell adhesion molecule-dependent motility and invasion. J Biol Chem 279: 28880-28888, 2004.
39. Whittard JD, Sakurai T, Cassella MR, Gazdoiu M, and Felsenfeld DP: MAP kinase pathway-dependent phosphorylation of the L1-CAM ankyrin-binding site regulates neuronal growth. Mol Biol Cell 17: 2696-2706, 2006.
40. Gast D, Riedle S, Kiefel H, Sebens Muerköster S, Schäfer H, Schäfer MKE and Altevogt P: The RGD integrin-binding site in human L1-CAM is important for nuclear signaling. Exp Cell Res 314: 2411-2418, 2008.
41. Primiano T, Baig M, Maliyekkel A, Chang BD, Fellars S, Sadhu J, Axenovich SA, Holzmayer TA and Roninson IB: Identification of potential anticancer drug targets through the selection of growth-inhibitory genetic suppressor elements. Cancer Cell 4: 41-53, 2003.
42. Gast D, Riedle S, Schabath H, Schlich S, Schneider A, Issa Y, Stoeck A Fogel M, Joumaa S, Wenger T, Gutwein P and Altevogt P: L1 augments cell migration and tumor growth but not beta3 integrin expression in ovarian carcinomas. Int J Cancer 115: 658-665, 2005.
43. Stoeck A, Schlich S, Issa Y, Gschwend V, Wenger T, Herr I, Marmé A, Bourbie S, Altevogt P and Gutwein P: L1 on ovarian carcinoma cells is a binding partner for Neuropilin-1 on mesothelial cells. Cancer Lett 239: 212-226, 2006.
44. Shutman M, Levina E, Ohouo P, Baig M and Roninson IB: Cell adhesion molecule L1 disrupts E-cadherin-containing adherens junctions and increases scattering and motility of MCF7 breast carcinoma cells. Cancer Res 66: 11370-11380, 2006.
45. Heiz M, Grünberg J, Schubiger PA and Novak-Hofer I: Hepatocyte growth factor-induced ectodomain shedding of cell adhesion molecule L1: role of the L1 cytoplasmic domain. J Biol Chem 279: 31149-31156, 2004.
46. Gutwein P, Stoeck A, Riedle S, Gast D, Runz S, Condon TP, Marmé A, Phong MC, Linderkamp O, Skorokhod A and Altevogt P: Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells. Clin Cancer Res 11: 2492-2501, 2005.
47. Friedli A, Fischer E, Novak-Hofer I, Cohrs S, Ballmer-Hofer K, Schubiger PA, Schibli R and Grünberg J: The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor. Int J Biochem Cell Biol 41: 1572-15801, 2009.
48. Stoeck A, Gast D, Sanderson MP, Issa Y, Gutwein P and Altevogt P: L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cellls. Gynecol Oncol 104: 461-469, 2007.
49. Sebens Muerköster S, Werbing V, Sipos B, Debus MA, Witt M, Grossmann M, Leisner D, Kötteritzsch J, Kappes H, Klöppel G, Altevogt P, Fölsch UR and Schäfer H: Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene 26: 2759-2768, 2007.
50. Euer NI, Kaul S, Deissler H, Mobus VJ, Zeillinger R and Weidle UH: Identification of L1CAM, Jagged2 and Neuromedin U as ovarian cancer-associated antigens. Oncol Rep 13: 375-387, 2005.
51. Itoh K, Sakurai Y, Asou H and Umeda M: Differential expression of alternatively spliced neural cell adhesion molecule L1 isoforms during oligodendrocyte maturation. J Neurosci Res 60: 579-586, 2000.
52. Jouet M, Rosenthal A and Kenwrick S: Exon 2 of the gene for neural cell adhesion molecule L1 is alternatively spliced in B-cells. Brain Res Mol Brain Res 30: 378-380, 1995.
53. Reid RA and Hemperly JJ: Variants of human L1 cell adhesion molecule arise through alternate splicing of RNA: J Mol Neurosci 3: 127-135, 1992.
54. Takeda Y, Asou H, Murakami Y, Miura M, Kobayashi M and Uyemura K: A non-neuronal isoform of cell adhesion molecule L1: tissue-specific expression and functional analysis. J Neurochem 66: 2338-2349, 1996.
55. De Angelis E, Brummendorf T, Cheng L, Lemmon V and Kenwrick S: Alternative use of a mini exon of the L1 gene affects L1 binding to neural ligands. J Biol Chem 276: 32738-32742, 2001.
56. Jacob J, Haspel J, Kane-Goldsmith N and Grumet M: L1 mediated homophilic binding and neurite outgrowth are modulated by alternative splicing of exon 2. J Neurobiol 51: 177-189, 2002.
57. Long KE, Asou H, Snider MD and Lemmon V: The role of endocytosis in regulating L1-mediated adhesion. J Biol Chem 276: 1285-1290, 2001.
58. Cheng L, Itoh K and Lemmon V: L1-mediated branching is regulated by two ezrin-radixin-moesin (ERM)-binding sites, the RSLE region and a novel juxtamembrane ERM-binding region. J Neurosci 25: 395-403, 2005.
59. Kamiguchi H and Lemmon V: A neuronal form of the cell adhesion molecule L1 contains a tyrosine-based signal required for sorting to the axonal growth cone. J Neurosci 18: 3749-3756, 1998.
60. Schaefer AW, Kamiguchi H, Wong EV, Beach CM, Landreth G and Lemmon V: Activation of the MAPK signal cascade by the neural cell adhesion molecule L1 requires L1 internalization. J Biol Chem 274: 37965-37973, 1999.
61. Panicker AK, Buhusi M, Erickson A and Maness PF: Endocytosis of betal integrins is an early event in migration promoted by the cell adhesion molecule L1. Exp Cell Res 31: 299-307, 2006.
62. Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R and Montuenga LM: Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol 8: 349-357, 2007.
63. Scotlandi K, Zuntini M, Manara MC, Sciandra M, Rocchi A, Benini S, Nicoletti G, Bernard G, Nanni P, Lollini PL, Bernard A and Picci P: CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity. Oncogene 26: 6604-6618, 2007.
64. Meli ML, Carrel F, Waibel R, Amstutz H, Crompton N, Jaussi R, Moch H, Schubiger PA and Novak-Hofer I: Anti-neuroblastoma antibody chCE7 binds to an isoform of L1-CAM present in renal carcinoma cells. Int J Cancer 83: 401-408, 2000.
65. Novak-Hofer I, Amstutz HP, Morgenthaler JJ and Schubiger PA: Internalization and degradation of monoclonal antibody chCE7 by human neuroblastoma cells. Int J Cancer 57: 427-432. 1994.
66. Amstutz HP, Rytz C, Novak-Hofer I, Spycher M, Schubiger PA, Blaser K and Morgenthaler JJ: Production and characterization of a mouse human chimeric antibody directed against human neuroblastoma. Int J Cancer 53: 147-152, 1993.
67. Grünberg J, Knogler K, Waibel R and Novak-Hofer I: High yield production of recombinant antibody fragments in HEK-293 cell using sodium butyrate. Biotechniques 34: 968-972, 2003.
68. Arlt MJE, Novak-Hofer I, Gast D, Gschwend V, Moldenhauer G, Grünberg J, Honer M, Schubiger PA, Altevogt P and Krüger A: Efficient inhibition of intraperitoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res 66: 936-943, 2006.
69. Novak-Hofer I, Cohrs S, Grünberg J, Friedli A, Schlatter M, Pfeifer M, Altevogt P and Schubiger P: Antibodies directed against L1-CAM synergize with genistein in inhibiting growth and survival pathways in SKOV3ip human ovarian cancer cells. Cancer Letters 261: 193-204, 2003.
70. Mechtersheimer S, Gutwein P, Agmon-Levin N, Stoeck A, Oleszewski M, Riedle S, Postina R, Fahrenholz F, Fogel M, Lemmon V and Altevogt P: Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol 155: 661-673, 2001.
71. Novak-Hofer I: The L1 cell adhesion molecule as a target for radioimmunotherapy. Cancer Biother Radiopharm 22: 175-184, 2007.
72. Novak-Hofer I, Carrel F, Armstutz H, Hasler P and Schubiger PA: Evaluation of different single chain constructs based on antineuroblastoma mab chCE7. Immunotechnology 2: 304-314, 1996.
73. 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties. Nucl Med Biol 33: 883-889, 2006.
74. Knogler K, Grünberg J, Zimmermann K, Cohrs S, Honer M, Ametamey S, Altevogt P, Fogel M, Schubiger PA and Novak-Hofer I: Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis. Clin Cancer Res 13: 603-611, 2007.
75. Hoefnagel CA, Rutgers M, Buitenhuis CA, Smets LA, de Kraker J, Meli M, Carrel F, Amstutz H and Novak-Hofer I: A comparison of targeting neuroblastoma with MLBG and anti-L1-CAM antibody mAbchCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients. Eur J Nucl Med 28: 359-368, 2001.
76. Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, Meechoovet HB, Bautista C, Chang WC, Ostberg JR and Jensen MC: Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 15: 825-833, 2007.